Search from website

Human IgG1-lambda antibody to SARS CoV-2 NP (clone 21F9)

 

Figure 1. Coomassie-stained SDS-PAGE analysis of monoclonal antibody to SARS-CoV-2 Nucleocapsid protein, clone 21F9. 4-12% gradient gel is used for analysis. Lane 1. Monoclonal antibody to SARS-CoV-2 Nucleocapsid protein, clone 21F9 (-DTT). Lane 2. Size marker. Lane 3. Monoclonal antibody to SARS-CoV-2 Nucleocapsid protein, clone 21F9 (+DTT). Lane 4. Size marker.

       

Figure 2. HPLC analytical SEC for final product.

       

Figure 3. HPLC analytical SEC after 3 freeze-thaw cycles.

       

Figure 4. Octet RED96e analysis, antibody was loaded on sensor for capture of Nucleocapsid protein.

Select volume:

Quantity:

Catalogue #

R1-148-100

Name

Human IgG1-lambda antibody to SARS CoV-2 NP (clone 21F9)

Target

Nucleocapsid protein SARS-CoV-2

Target Description

Recombinant SARS-CoV-2 Nucleocapsid protein produced by CHO-based Icosagen Cell factory Ltd. proprietary suspension cell line

Clonality

Human monoclonal

Clone

21F9

Class

hIgG1

Reactivity

SARS-CoV-2 Nucleocapsid protein

Dissociation constant (KD)

3.42 x 10-10 M

Application

ELISA, WB

Kd:

3.42 x 10-10 M

ELISA:

0,63-1,25 µg/ml

WB:

0,5-1 µg/ml

Purification

Protein A affinity chromatography following desalting

Buffer

PBS pH 7.4

Shipping

Shipped at ambient temperature.

Storage

Store at -20 °C to -70 °C long term.
Avoid multiple freeze-thaw cycles.

This product is for research use only

TECHNICAL ASSISTANCE

Please refer any technical questions to

technical.support@icosagen.com

Our locations

United States Office

77 Geary St. 5th Floor
San Francisco, CA 94108
+1 415 548 6625

European Office

Eerika tee 1
Õssu, Kambja vald
Tartu maakond 61713
Estonia
+372 737 7070
error:
Shopping Cart